Mouse Study Finds Porcine Collagen Injections Regrow Elastic Fibers in Aging Skin

A study published in the Journal of Cosmetic Dermatology reports that injecting a porcine-derived form of collagen under the skin of mice triggered the growth of new elastic fibers, the structures that let skin snap back into place rather than sag. The researchers, led by Seung Min Oh and colleagues, tested the material in both young mice (4 months old) and naturally aged mice (15 months old), collecting skin samples 2 and 4 weeks after treatment.

The ingredient itself is worth pinning down before the results: atelocollagen is Type I collagen that has had its telopeptide ends enzymatically clipped off. Those end regions are what typically trigger immune recognition, so removing them is meant to lower the chance of an allergic or inflammatory reaction when animal-derived collagen is injected into human or animal tissue. The version tested here was sourced from pig skin and described by the authors as low-immunogenic and transparent, a formulation detail relevant to injectable clarity rather than to how it performs biologically.

To confirm the material was doing more than just adding bulk under the skin, the team used Verhoeff staining, a technique that selectively marks elastic fibers, alongside standard hematoxylin and eosin staining for overall tissue structure. Verhoeff-stained sections showed newly formed elastic fibers extending into the upper dermis of the aged mice, an architecture the authors describe as resembling that of young skin. They also tracked eight genes tied to elastic fiber assembly, including Eln, Fbn1, and Lox, to check that the regeneration had a genetic signature behind it rather than being an artifact of staining.

The paper also addresses a safety question that matters for any injectable: whether the body treats the material as a foreign irritant long-term. The authors found a transient activation of M2 macrophages, immune cells associated with tissue repair and remodeling rather than active infection-fighting, during the early response window. By four weeks, there was no histological evidence of persistent inflammation, which the authors frame as evidence of favorable biocompatibility.

What the paper does not do is test this in humans. The word "skin booster," used throughout the abstract to describe the product category, refers to a class of injectable cosmetic treatments that already circulate in aesthetic medicine, but the study itself is a preclinical, mouse-only experiment, and the authors explicitly call for further investigation of molecular mechanisms and long-term clinical efficacy before any of these findings translate to marketed claims. No specific commercial product or brand is named in connection with the material tested.